** Shares of Divi's Laboratories DIVI.NS rise 5.7% to
two-year high of 4,359 rupees, rallying for 6th session in a row
** DIVI's top gainer on benchmark Nifty 50 .NSEI and
pharma index .NIPHARM
** Co's Q4 consol net profit rose ~68% Y/Y on strong demand
** Motilal Oswal expects DIVI to gain market share and
maintain profitability in active pharmaceutical ingredients
(API) portfolio
** Prabhudas Lilladher says gross margins stabilized, likely
to improve on better product mix and stable raw material prices
** Trading vol is over 4x the 30-day avg, busiest day in a
year
** DIVI up 10% YTD, more than the Nifty 50 (~6%), but less
than pharma index (~14%)
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))